NCT00157079View on ClinicalTrials.gov

Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders

PHASE3CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

June 25, 2002

Primary Completion Date

December 16, 2003

Study Completion Date

December 16, 2003

Conditions
Primary Immunodeficiency Diseases (PID)Immune Thrombocytopenic Purpura (ITP)Kawasaki Syndrome
Interventions
BIOLOGICAL

Immune Globulin Intravenous (Human), 10%

Trial Locations (11)

10461

Montefiore Medical Center, Albert Einstein College of Medicine, The Bronx

33408

Allergy Associates of the Palm Beaches, North Palm Beach

33613

University of South Florida; Asthma, Allergy & Immunology CRU, Tampa

60612

Rush Presbyterian - St. Lukes Medical Center, Chicago

68046

Asthma and Allergy Center, Papillion

68124

Allergy, Asthma & Immunology Assoc., Omaha

75230

Pediatric Allergy/Immunology Associates, Dallas

80112

1st Allergy and Clinical Research Center, Englewood

90027

Children´s Hospital Los Angeles, Los Angeles

94304-8786

Stanford University Medical Center, Stanford

02115

Children´s Hospital Boston, Boston

All Listed Sponsors
lead

Baxalta now part of Shire

INDUSTRY

NCT00157079 - Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders | Biotech Hunter | Biotech Hunter